The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Sarcoidosis
The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).
Use of CXCL9 as a Biomarker of Acthar Efficacy
-
University of California, San Francisco, San Francisco, California, United States, 94143
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to 65 Years
ALL
No
University of California, San Francisco,
Laura Koth, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco
2026-12